Esmo15 Sep 2025 12:27
Going in the below I am assuming this could also include some data and insights from Phase 1b as they have just stated Phase 1 below?
Title: A Phase I trial of FAP-Dox (AVA6000), a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors
Session Title: Developmental Therapeutics
Session Date and Time: 19 October, 12.00-12.45
Location: Hall 25
Abstract Presentation Number: 964P
Speaker: William D. Tap